Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MGY825 |
Synonyms | |
Therapy Description |
MGY825 inhibits NFE2L2, KEAP1, and CUL3, which potentially leads to decreased tumor cell proliferation (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MGY825 | MGY 825|MGY-825 | MGY825 inhibits NFE2L2, KEAP1, and CUL3, which potentially leads to decreased tumor cell proliferation (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05275868 | Phase I | MGY825 | Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer | Recruiting | USA | ESP | DEU | CHE | 2 |